“Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs industry and market set to grow to $23bn by 2024” says Visiongain report

31 July 2019
Pharma

Visiongain has launched a new pharma report Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2019-2029: Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis, Eylea, Avastin, Visudyne.

The sector has obvious growth potential, since the majority of the AMD and DR patient population currently still lack any treatment options. This means that there are vast patient populations for manufacturers to target with new AMD and DR products, and new candidates in these areas can hope for fast track status from regulatory bodies.

The lead analyst of the report commented "Another question-mark that hangs over the future of the AMD and DR pharmaceuticals sector is the widespread belief that the best cure for these conditions is not biological or small-molecule drug interventions that can stabilise or reverse disease progression, but rather prevention: a therapeutic approach that can stop AMD and DR developing in the first place is widely seen as the major goal by scientists and clinicians working in the field."

Leading companies featured in the report include Acucela, Inc., Allergan Plc, Bayer AG, F. Hoffman-La Roche, Ltd., GlaxoSmithKline Pharmaceuticals, Ltd., Novartis AG, Pfizer, Inc., Valent Pharmaceuticals International, Plc and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

Read

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

Read

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

Read

Visiongain Publishes Drug Discovery Outsourcing Market Report 2020-2030

The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.

07 September 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever